Key Insights Fatigue is a common but usually temporary side effect during the initial weeks or dose changes in GLP-1 therapy, caused largely by rapid calorie deficit, dehydration, and metabolic adjustments. Maintaining steady energy requires prioritising nutrient-dense meals rich in protein and complex carbohydrates, staying well hydrated, and managing electrolyte balance, which helps mitigate tiredness and supports overall metabolism. Gentle physical activity and good sleep hygiene are critical lifestyle adjustments that improve circulation, mood, and energy levels without overtaxing the body during the drug adaptation period. Persistent, worsening, or debilitating fatigue should prompt medical evaluation to exclude other causes, reassess medication dosing, and ensure safe continuation of GLP-1 therapy under healthcare supervision. Frequently asked questions Why do GLP-1 medications cause fatigue
One has a reasonable case
: 50
Advances and prospects of phenolic acids production, biorefinery and analysis
some evaluations are handled asynchronously through form review
The most commonly reported changes after stopping GLP-1 medications include: Return of appetite : The appetite-suppressing effects diminish, and many people notice increased hunger and food cravings returning to pre-treatment levels Weight regain : Clinical evidence consistently shows that most individuals regain weight after discontinuation, often within 312 months Rising blood glucose levels : For those with type 2 diabetes, HbA1c levels typically increase, sometimes returning to pre-treatment values Changes in eating patterns : Gastric emptying returns to normal speed, which may affect feelings of fullness after meals It's important to note that stopping GLP-1 medications is generally safe from a withdrawal perspectivethese drugs do not cause physical dependence or withdrawal symptoms in the way some medications do, and tapering is not typically required